{
  "id": 3611,
  "text": "J Clin Oncol 27, 1069-1074 (2009).1602.Lorusso, D., et al.Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: J Clin Oncol 27, 1069-1074 (2009).1602.Lorusso, D., et al.Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.\n\n<question>: ",
  "ChatGPT_response_0": "根据《MITO (多中心意大利卵巢癌和妇科恶性肿瘤试验）集团》的研究，在宫颈癌持续性或复发性的第二线化疗中，药物博来胺（pemetrexed）被评估为一种潜在的选择。",
  "query": "研究中提到了什么药物作为宫颈癌持续性或复发性的第二线化疗？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 研究中提到了什么药物作为宫颈癌持续性或复发性的第二线化疗？\n\n<reference text>: J Clin Oncol 27, 1069-1074 (2009).1602.Lorusso, D., et al.Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.\n\n<reply>: ",
  "response": "根据《MITO (多中心意大利卵巢癌和妇科恶性肿瘤试验）集团》的研究，在宫颈癌持续性或复发性的第二线化疗中，药物博来胺（pemetrexed）被评估为一种潜在的选择。"
}